Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
02 October 2018 | Story UFS | Photo Valentino Ndaba
UFS BRICS-PLUS tackles global challenges
Dr Thulisile Mphambukeli (UFS), Dr Fidelia Dake (University of Ghana), and Dr Victor Okorie (UFS).

Over 70% of the earth is water yet more than two billion people lack access to clean water and sanitation. About 795 million people are food insecure but one third of all food produced in the world, which worth $1.6 billion, is thrown into the dustbin every year. These are the problems, the paradoxes, which seasoned social scientists, engineers and clinicians from universities, research institutions and non-governmental organisations in South Africa, Russia, India, Ghana, Nigeria, and Zimbabwe deliberated at the BRICS-PLUS conference.

The scholars also noted that the grim statistics of water and food-related human suffering, including illnesses, are on not only the increase but overweight and underweight now co-exist in the same household. Dr Victor Okorie, a Postdoctoral Fellow and Dr Thulisile Mphambukeli, a senior lecturer at the Department of Urban and Regional Planning at the University of Free State (UFS), along with Prof Lere Amusan of the North-West University, successfully hosted the first BRICS-PLUS Conference themed: Water, Food and Health Nexus in BRICS-PLUS: Problems, Progress and Prospects were the topics discussed.

The delegates collectively identified some drivers of the problematic paradoxes: including accelerated climate change, urbanisation, inequality, inequity, and population growth. Others were a move from family to factory food and limited physical activity, among other unhealthy lifestyles.

Recommendations based on observation

After the delegates deliberated on various issues of water, food and health nexus in BRICS-PLUS, they made the following policy recommendations:
• There should be strong collaboration among critical stakeholders such as the state, civil society and knowledge institutions with respect to reducing the challenges of water, food and health.

• Issues of gender and the youth should be explicitly incorporated into policies guiding water, food and health nexus across BRICS-PLUS.

• The BRICS-Plus research team should be upgraded into a more permanent organisation in order to strengthen how it deals with the challenges at hand.

• There is a need to balance competing uses of water and other natural resources to prevent further pollution and destruction of the commons.

• Investments in research on water, food and health to generate innovations for sustainable development should inform BRICS’ science, technology and innovation agenda.

• There is a need to promote a zero-waste circular economy through recycling in production, preservation, processing, more equitable distribution and consumption processes to reduce ecological footprints across BRICS-PLUS, and generate energy for sustainable economy.

• It’s necessary to encourage technology transfer, capacity-building and policy learning among member-states

• BRICS should encourage favourable terms of trade among member states with respect to water, food and health issues.

News Archive

Cardiology Unit involved in evaluation of drug for rare genetic disease
2013-01-04

Front from the left, are: Marinda Karsten (study coordinator and registered nurse),
Laumarie de Wet (clinical technologist), Charmaine Krahenbuhl (study coordinator and radiographer),
Lorinda de Meyer (administrator), Andonia Page (study coordinator and enrolled nurse);
back Dr Gideon Visagie (sub investigator), Dr Derick Aucamp (sub investigagtor),
Prof. Hennie Theron, (principal investigator) and Dr Wilhelm Herbst (sub investigator).
Photo: Supplied
09 January 2013


The Cardiology Research Unit at the University of the Free State (UFS) contributed largely to the evaluation of the drug Juxtapid (lomitapide), which was developed by the Aegerion pharmaceutical company and approved by the FDA (Federal Drug Administration). Together with countries such as die USA, Canada and Italy, the UFS’ Unit recruited and evaluated the most patients (5 of 29) for the study since 2008.  

The drug was evaluated in persons with so-called familial homozygous hypercholesterolemia (HoFH).  

Following its approval by the FDA, Juxtapid is now a new treatment option for patients suffering from HoFH. The drug operates in a unique way which brings about dramatic improvements in cholesterol counts.  

According to Prof. Hennie Theron, Associate Professor in the Department of Cardiology at the UFS and Head of the Cardiology Contract Research Unit, HoFH is a serious, rare genetic disease which affects the function of the receptor responsible for the removal of low-density lipoprotein cholesterol (LDL-C) (“bad” cholesterol) from the body. Damage to the LDL receptor function leads to extremely high levels of blood cholesterol. HoFH patients often develop premature and progressive atherosclerosis, which is a narrowing or blockage of the arteries.  

“HoFH is a genetically transmitted disease and the most severe form of hypercholesterolemia. Patients often need a coronary artery bypass or/and aortic valve replacement before the age of 20. Mortality is extremely high and death often occurs before the third decade of life. Existing conventional cholesterol-lowering medication is unsuccessful in achieving normal target cholesterol values in this group of patients.  

“The only modality for treatment is plasmapheresis (similar to dialysis in patients with renal failure). Even with this type of therapy the results are relatively unsatisfactory because it is very expensive and the plasmapheresis has to be performed on a regular basis.  

“The drug Juxtapid, as currently evaluated, has led to a dramatic reduction in cholesterol values and normal values were achieved in several people. No existing drug is nearly as effective.  

“The drug represents a breakthrough in the treatment of familial homozygous hypercholesterolemia. The fact that it has been approved by the FDA, gives further impetus to the findings,” says Prof. Theron.  

In future further evaluation will be performed in other forms of hypocholesterolemia.  

According to Prof. Theron, the findings of the study, as well as the recent successful FDA evaluation, once again confirms the fact that the UFS’ Cardiology Contract Research Unit is doing outstanding work.  

Since its inception in 1992, the Unit has already been involved in more than 60 multi-centre, international phase 2 and 3 drug studies. Several of these studies, including the abovementioned study, really affected the way in which cardiology functions.  

The UFS’ Cardiology Contract Research Unit is being recognised nationally and internationally for its high quality of work and is constantly approached for their involvement in new studies.  

We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept